| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
|
Medical response |
|
Sinopharm NVSI COVID-19 vaccine, also known asmutI-tri-RBD orNVSI-06-08, is aCOVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG ofSinopharm.[2][3]
They claim to be the world's first "second generation broadly protective" recombinationprotein subunitvaccine, i.e. by combining three heterogeneousantigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).[4] It's based on the original, and theBeta (K417N/E484K/N501Y) andKappa (L452R/E484K) variants.[5]
This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |